Recombinant Anti-Aurora A antibody [EP1008Y] (ab52973)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EP1008Y] to Aurora A
- Suitable for: WB, IP, IHC-P
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-Aurora A antibody [EP1008Y]
See all Aurora A primary antibodies -
Description
Rabbit monoclonal [EP1008Y] to Aurora A -
Host species
Rabbit -
Tested applications
Suitable for: WB, IP, IHC-Pmore details
Unsuitable for: Flow Cyt or ICC/IF -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide within Human Aurora A aa 350-450 (C terminal). The exact sequence is proprietary.
-
Positive control
- HepG2 nuclear cell lysate Human cervical carcinoma tissue IP: HepG2 whole cell lysate.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 50% Tissue culture supernatant -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EP1008Y -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab52973 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | (1) |
1/50000. Detects a band of approximately 46 kDa (predicted molecular weight: 46 kDa).
|
IP |
1/50.
|
|
IHC-P |
1/100 - 1/250. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
|
Notes |
---|
WB
1/50000. Detects a band of approximately 46 kDa (predicted molecular weight: 46 kDa). |
IP
1/50. |
IHC-P
1/100 - 1/250. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. |
Target
-
Function
Contributes to the regulation of cell cycle progression. Required for normal mitosis. Associates with the centrosome and the spindle microtubules during mitosis and functions in centrosome maturation, spindle assembly, maintenance of spindle bipolarity, centrosome separation and mitotic checkpoint control. Phosphorylates numerous target proteins, including ARHGEF2, BRCA1, KIF2A, NDEL1, PARD3, PLK1 and BORA. Regulates KIF2A tubulin depolymerase activity (By similarity). Required for normal axon formation. Plays a role in microtubule remodeling during neurite extension. Important for microtubule formation and/or stabilization. -
Tissue specificity
Highly expressed in testis and weakly in skeletal muscle, thymus and spleen. Also highly expressed in colon, ovarian, prostate, neuroblastoma, breast and cervical cancer cell lines. -
Sequence similarities
Belongs to the protein kinase superfamily. Ser/Thr protein kinase family. Aurora subfamily.
Contains 1 protein kinase domain. -
Post-translational
modificationsActivated by phosphorylation at Thr-288; this brings about a change in the conformation of the activation segment. Phosphorylation at Thr-288 varies during the cell cycle and is highest during M phase. Autophosphorylated at Thr-288 upon TPX2 binding. Phosphorylated upon DNA damage, probably by ATM or ATR.
Ubiquitinated by CHFR, leading to its degradation by the proteasome (By similarity). Ubiquitinated by the anaphase-promoting complex (APC), leading to its degradation by the proteasome. -
Cellular localization
Cytoplasm > cytoskeleton > centrosome. Cytoplasm > cytoskeleton > spindle pole. Detected at the neurite hillock in developing neurons (By similarity). Localizes on centrosomes in interphase cells and at each spindle pole in mitosis. - Information by UniProt
-
Database links
- Entrez Gene: 6790 Human
- Omim: 603072 Human
- SwissProt: O14965 Human
- Unigene: 250822 Human
-
Alternative names
- AIK antibody
- ARK-1 antibody
- ARK1 antibody
see all
Images
-
Anti-Aurora A antibody [EP1008Y] (ab52973) at 1/50000 dilution + HepG2 (Human liver hepatocellular carcinoma cell line) cell lysate at 10 µg
Secondary
Goat anti-rabbit HRP at 1/2000 dilution
Predicted band size: 46 kDa
Observed band size: 46 kDa -
Formalin-fixed, paraffin-embedded human cervical carcinoma tissue stained for Aurora A with ab52973 (1/100 dilution) in immunohistochemical analysis. Inset panel is a larger magnification of the image.
Inset panel is a larger magnification of the image.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
-
Purified ab52973 at 1/50 dilution (2µg) immunoprecipitating Aurora A in HepG2 whole cell lysate.
Lane 1 (input): HepG2 (Human hepatocellular carcinoma epithelial cell) whole cell lysate 10µg
Lane 2 (+): ab52973 + HepG2 whole cell lysate.
Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab52973 in HepG2 whole cell lysate.
VeriBlot for IP Detection Reagent (HRP) (ab131366) (1/1000 dilution) was used for Western blotting.
Blocking Buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM/TBST.
Observed band size: 46 kDa
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (12)
ab52973 has been referenced in 12 publications.
- Hao J et al. Antitumor Effect of Lenvatinib Combined with Alisertib in Hepatocellular Carcinoma by Targeting the DNA Damage Pathway. Biomed Res Int 2021:6613439 (2021). PubMed: 34337035
- Chi YH et al. Discovery and Synthesis of a Pyrimidine-Based Aurora Kinase Inhibitor to Reduce Levels of MYC Oncoproteins. J Med Chem 64:7312-7330 (2021). PubMed: 34009981
- Liu C et al. Gambogenic Acid Induces Endoplasmic Reticulum Stress in Colorectal Cancer via the Aurora A Pathway. Front Cell Dev Biol 9:736350 (2021). PubMed: 34692693
- Rendo V et al. Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy. Nat Commun 11:1308 (2020). PubMed: 32161261
- Jiang J et al. Identification of Aurora Kinase A as a Biomarker for Prognosis in Obesity Patients with Early Breast Cancer. Onco Targets Ther 13:4971-4985 (2020). PubMed: 32581556